What’s driving the surge in advanced prostate cancer cases worldwide?

Advanced prostate cancer cases are rising worldwide as fewer men undergo routine PSA screening and early symptoms go ...
Morningstar

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...
Seeking Alpha

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...
The News International

Prostate cancer care takes major step to prevent severe treatment pain

A new way to prevent excruciating pain from the side effects of advanced prostate cancer therapy has been developed.Many men ...
STATOpinion

Did my prostate cancer screening do more harm than good?

Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...